WeMed

WeMed Medical has established itself as one of China’s few companies offering a complete product portfolio for interventional procedures, spanning vascular intervention robots, digital subtraction angiography (DSA) systems, and mobile C-arm devices. Founded in 2014 and headquartered in Beijing’s Economic-Technological Development Area, the company pursues an integrated “Eye-Hand-Brain” strategy that combines advanced imaging, robotic manipulation, and AI-powered analysis.

Company Overview

WeMed Medical focuses exclusively on interventional diagnosis and treatment equipment, positioning itself as a full-solution provider for minimally invasive vascular procedures. The company’s founding team brings over 15 years of experience in digital vascular imaging system design and commercialization.

The company expanded its international footprint in 2016 through the acquisition of EC, one of Italy’s three major mobile C-arm brands, establishing a dual-center development model spanning China and Europe. This strategic move enabled WeMed to build on European manufacturing expertise while accelerating domestic innovation.

WeMed has secured ISO 13485 certification and obtained both CE and NMPA approvals across its product lines. The company operates as a National High-Tech Enterprise and participated in drafting national standards for interventional surgery robots, helping define key performance metrics including axial movement, rotation parameters, and safety features.

Core Products

ETcath Vascular Intervention Robot

The ETcath system represents WeMed’s flagship innovation in surgical robotics. Approved by NMPA in March 2025, it became the world’s first interventional surgery robot integrating “Eye-Hand-Brain” functionality. The system enables remote-controlled manipulation of catheters, guidewires, balloons, and stents during vascular interventions.

Key specifications include imaging precision at 0.1mm level (five times more accurate than human vision), robotic arm motion control with errors below 0.05mm, and force sensing capability as low as 0.01 Newtons. The ETcath holds over 100 patents, with 80% being invention patents.

Aurora DSA System

WeMed’s 7-axis flat-panel DSA system (Aurora/极光) achieved a significant milestone in 2020 by becoming the first domestic high-end DSA to receive both NMPA and CE certification. The system has been installed at major institutions including Beijing Tiantan Hospital, First Affiliated Hospital of Zhengzhou University, and Zhengzhou Central Hospital.

Mobile C-arm Series

The company offers a broad range of mobile C-arm systems covering surgical (small C), interventional (medium C), and hybrid operating room applications. The Alien E platform, acquired through the Italian EC acquisition, has been sold in over 20 countries across more than a decade.

Technology & Innovation

WeMed’s technological differentiation centers on its integrated “Eye-Hand-Brain” ecosystem:

• Eye: Self-developed DSA equipment with AI algorithms provides submillimeter-level lesion identification
• Hand: The ETcath robotic system acts as an intelligent bionic manipulator for catheter and guidewire control
• Brain: AI-powered imaging analysis platform enables real-time surgical guidance and decision support

The company has developed proprietary bionic guidewire control technology and an internationally pioneering flexible guidewire resistance detection system. These capabilities allow the ETcath to support the full spectrum of interventional procedures including guidewire manipulation, balloon delivery, stent deployment, and IVUS catheter operation.

Market Presence

WeMed operates in the rapidly expanding Chinese interventional market, where coronary intervention procedures exceeded 1.16 million cases in 2021 with annual growth rates above 15%. The company’s DSA and C-arm products have gained traction in provincial tenders, while the ETcath system targets the emerging vascular intervention robot segment.

The dual-center model connecting Beijing and Italy supports both domestic market development and international expansion across European, Asian, and Middle Eastern markets.

Key Milestones

• 2014: Company founded in Beijing
• 2016: Acquired Italian EC mobile C-arm brand
• 2019: ETcath prototype developed
• 2020: Aurora DSA received NMPA and CE dual certification
• 2021 (October 8): First domestically-developed PCI surgery using ETcath, performed by Professor Zhou Yujie’s team at Beijing Anzhen Hospital
• 2022: Series D funding exceeding ¥300M led by K2 Capital
• 2025 (March 21): ETcath received NMPA approval
• 2025 (October): ETcath200 selected for Beijing’s First Major Technical Equipment Catalog

Frequently Asked Questions

What is WeMed’s ETcath vascular intervention robot?

ETcath is a vascular interventional surgery robot that enables physicians to remotely control catheters, guidewires, balloons, and stents during PCI and other vascular procedures. It integrates with DSA imaging and AI analysis to provide an “Eye-Hand-Brain” surgical solution. The system received NMPA approval in March 2025.

Has WeMed performed clinical surgeries with its robot?

Yes. In October 2021, Professor Zhou Yujie’s team at Beijing Anzhen Hospital performed the first-ever PCI surgery using a domestically-developed vascular intervention robot. The procedure included guidewire manipulation, balloon dilation, and coronary stent implantation, all completed by the ETcath system.

What funding has WeMed received?

WeMed has completed multiple funding rounds including Series C+ (¥100M from Hillhouse Ventures) and Series D (over ¥300M led by K2 Capital with participation from Suzhou Longmen Ventures, LP Capital, and Luxin Ventures).